Stanojević, N

Link to this page

Authority KeyName Variants
b04ce8e8-5f73-4a99-93a5-249b83578b27
  • Stanojević, N (2)
Projects
No records found.

Author's Bibliography

Apolipoprotein E polymorphism and severity of angiographically verified coronary artery disease

Spasojević-Kalimanovska, Vesna; Kalimanovska-Oštrić, Dimitra; Jelić-Ivanović, Zorana; Topić, Aleksandra; Stanković, S; Stanojević, N

(Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd, 1999)

TY  - JOUR
AU  - Spasojević-Kalimanovska, Vesna
AU  - Kalimanovska-Oštrić, Dimitra
AU  - Jelić-Ivanović, Zorana
AU  - Topić, Aleksandra
AU  - Stanković, S
AU  - Stanojević, N
PY  - 1999
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/220
AB  - Apolipoprotein E is an important genetic determinant of serum lipoprotein concentrations and coronary artery disease risk. The apo E polymorphism is a major determinant of interindividual variation in the initiation and progression of atherosclerosis. Differences in the gene sequence cause structural changes strongly affecting binding properties of the corresponding apo E isoforms. The presence of the epsilon 2 allele leads to LDL receptor upregulation and increased LDL clearance. In contrast the presence of the epsilon 4 allele leads to receptor down regulation and decreased LDL clearance. For most populations, individuals with the apo epsilon 2 allele display lower levels of plasma cholesterol compared with individuals carrying the apo epsilon 3 allele, whereas individuals with the apo epsilon 4 allele show higher levels of plasma cholesterol, especially LDL-cholesterol and an increased risk for cardiovascular disease. ApoE polymorphism explains near 7% of the variation in total, LDL cholesterol and apo B levels. To examine whether the polymorphism in the apo E gene is associated with CAD in our population, we analyzed 94 patients with angiographically verified CAD and in 45 patients with excluded CAD as a control group. The apo E phenotype was determined with isoelectric Focusing and Western immunoblotting technique using commercial antibodies. Patients were divided into three groups according to arteriograms as category: 1. mild, evidence of narrowing of one coronary artery >60% (39); 2. moderate, narrowing of two major coronary arteries (30) and 3. Severe, narrowing of all three major coronary arteries (25). The apo E allele frequencies of patients with CAD vs without CAD were 4.2% vs 7.7% For epsilon 2; 86.7% vs 85.5% for epsilon 3 and 9.1% vs 6.6%; for epsilon 4. The frequency of allele epsilon 4 was higher in patients with 3 vessel CAD than in patients without CAD (12% vs 6.6%) but it did not reach the statistical significance (chi(2)= 0.83, p = 0.36, d.f. 1). The Odds ratio for risk of CAD associated with the presence of apo epsilon 4 allele was 1.39 and for the phenotype E3/4 1.60. Our preliminary results suggest that the presence of apo epsilon 4 allele may impose some risk for developing CAD and that apo E determines the severity of CAD.
PB  - Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd
T2  - Jugoslovenska medicinska biohemija
T1  - Apolipoprotein E polymorphism and severity of angiographically verified coronary artery disease
VL  - 18
IS  - 2-3
SP  - 99
EP  - 105
UR  - https://hdl.handle.net/21.15107/rcub_farfar_220
ER  - 
@article{
author = "Spasojević-Kalimanovska, Vesna and Kalimanovska-Oštrić, Dimitra and Jelić-Ivanović, Zorana and Topić, Aleksandra and Stanković, S and Stanojević, N",
year = "1999",
abstract = "Apolipoprotein E is an important genetic determinant of serum lipoprotein concentrations and coronary artery disease risk. The apo E polymorphism is a major determinant of interindividual variation in the initiation and progression of atherosclerosis. Differences in the gene sequence cause structural changes strongly affecting binding properties of the corresponding apo E isoforms. The presence of the epsilon 2 allele leads to LDL receptor upregulation and increased LDL clearance. In contrast the presence of the epsilon 4 allele leads to receptor down regulation and decreased LDL clearance. For most populations, individuals with the apo epsilon 2 allele display lower levels of plasma cholesterol compared with individuals carrying the apo epsilon 3 allele, whereas individuals with the apo epsilon 4 allele show higher levels of plasma cholesterol, especially LDL-cholesterol and an increased risk for cardiovascular disease. ApoE polymorphism explains near 7% of the variation in total, LDL cholesterol and apo B levels. To examine whether the polymorphism in the apo E gene is associated with CAD in our population, we analyzed 94 patients with angiographically verified CAD and in 45 patients with excluded CAD as a control group. The apo E phenotype was determined with isoelectric Focusing and Western immunoblotting technique using commercial antibodies. Patients were divided into three groups according to arteriograms as category: 1. mild, evidence of narrowing of one coronary artery >60% (39); 2. moderate, narrowing of two major coronary arteries (30) and 3. Severe, narrowing of all three major coronary arteries (25). The apo E allele frequencies of patients with CAD vs without CAD were 4.2% vs 7.7% For epsilon 2; 86.7% vs 85.5% for epsilon 3 and 9.1% vs 6.6%; for epsilon 4. The frequency of allele epsilon 4 was higher in patients with 3 vessel CAD than in patients without CAD (12% vs 6.6%) but it did not reach the statistical significance (chi(2)= 0.83, p = 0.36, d.f. 1). The Odds ratio for risk of CAD associated with the presence of apo epsilon 4 allele was 1.39 and for the phenotype E3/4 1.60. Our preliminary results suggest that the presence of apo epsilon 4 allele may impose some risk for developing CAD and that apo E determines the severity of CAD.",
publisher = "Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd",
journal = "Jugoslovenska medicinska biohemija",
title = "Apolipoprotein E polymorphism and severity of angiographically verified coronary artery disease",
volume = "18",
number = "2-3",
pages = "99-105",
url = "https://hdl.handle.net/21.15107/rcub_farfar_220"
}
Spasojević-Kalimanovska, V., Kalimanovska-Oštrić, D., Jelić-Ivanović, Z., Topić, A., Stanković, S.,& Stanojević, N.. (1999). Apolipoprotein E polymorphism and severity of angiographically verified coronary artery disease. in Jugoslovenska medicinska biohemija
Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd., 18(2-3), 99-105.
https://hdl.handle.net/21.15107/rcub_farfar_220
Spasojević-Kalimanovska V, Kalimanovska-Oštrić D, Jelić-Ivanović Z, Topić A, Stanković S, Stanojević N. Apolipoprotein E polymorphism and severity of angiographically verified coronary artery disease. in Jugoslovenska medicinska biohemija. 1999;18(2-3):99-105.
https://hdl.handle.net/21.15107/rcub_farfar_220 .
Spasojević-Kalimanovska, Vesna, Kalimanovska-Oštrić, Dimitra, Jelić-Ivanović, Zorana, Topić, Aleksandra, Stanković, S, Stanojević, N, "Apolipoprotein E polymorphism and severity of angiographically verified coronary artery disease" in Jugoslovenska medicinska biohemija, 18, no. 2-3 (1999):99-105,
https://hdl.handle.net/21.15107/rcub_farfar_220 .

The role of transforming growth factor-beta in identifying patients with coronary artery disease

Stanojević, N; Jelić-Ivanović, Zorana; Durović, S; Spasojević-Kalimanovska, Vesna

(Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd, 1999)

TY  - JOUR
AU  - Stanojević, N
AU  - Jelić-Ivanović, Zorana
AU  - Durović, S
AU  - Spasojević-Kalimanovska, Vesna
PY  - 1999
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/212
AB  - Transforming growth factor-beta (TGF-beta) is a cytokine with antiatherogenic propretis. The active form of TGF-beta inhibits the activation of endothelial cells, and acts on vascular smooth muscle cells by inhibiting their migration, dediferentiation and proliferation. Lipoprotein (a) i PAI-1 interfere with plasmin-mediated TGF-beta activation by inhibiting the conversion of plasminogen to plasmin. Genetic polymorphism in the TGF beta(1) gene promoter were shown to be correlated with total TGF-beta concentrations, as measured by ELISA after acetic acid/urea activation. Althought many patients with coronary artery disease (CAD) have total TGF-beta concentration below the detection limit, the ability of total TGF-beta assay in discriminating between patients with CAD and individuals with normal coronary arteries is rather limited. Very significant inverse relationship between the concentration of active TGF-beta and CAD was found in several retrospective studies. Minor overlapping between the values in CAD patients and controls was obtained, demostrating the potential of the active TGF-beta as a new marker of CAD, superior to any of the conventional risk factors.
PB  - Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd
T2  - Jugoslovenska medicinska biohemija
T1  - The role of transforming growth factor-beta in identifying patients with coronary artery disease
VL  - 18
IS  - 2-3
SP  - 85
EP  - 89
UR  - https://hdl.handle.net/21.15107/rcub_farfar_212
ER  - 
@article{
author = "Stanojević, N and Jelić-Ivanović, Zorana and Durović, S and Spasojević-Kalimanovska, Vesna",
year = "1999",
abstract = "Transforming growth factor-beta (TGF-beta) is a cytokine with antiatherogenic propretis. The active form of TGF-beta inhibits the activation of endothelial cells, and acts on vascular smooth muscle cells by inhibiting their migration, dediferentiation and proliferation. Lipoprotein (a) i PAI-1 interfere with plasmin-mediated TGF-beta activation by inhibiting the conversion of plasminogen to plasmin. Genetic polymorphism in the TGF beta(1) gene promoter were shown to be correlated with total TGF-beta concentrations, as measured by ELISA after acetic acid/urea activation. Althought many patients with coronary artery disease (CAD) have total TGF-beta concentration below the detection limit, the ability of total TGF-beta assay in discriminating between patients with CAD and individuals with normal coronary arteries is rather limited. Very significant inverse relationship between the concentration of active TGF-beta and CAD was found in several retrospective studies. Minor overlapping between the values in CAD patients and controls was obtained, demostrating the potential of the active TGF-beta as a new marker of CAD, superior to any of the conventional risk factors.",
publisher = "Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd",
journal = "Jugoslovenska medicinska biohemija",
title = "The role of transforming growth factor-beta in identifying patients with coronary artery disease",
volume = "18",
number = "2-3",
pages = "85-89",
url = "https://hdl.handle.net/21.15107/rcub_farfar_212"
}
Stanojević, N., Jelić-Ivanović, Z., Durović, S.,& Spasojević-Kalimanovska, V.. (1999). The role of transforming growth factor-beta in identifying patients with coronary artery disease. in Jugoslovenska medicinska biohemija
Društvo medicinskih biohemičara Srbije i Crne Gore, Beograd i Univerzitet u Beogradu - Farmaceutski fakultet, Beograd., 18(2-3), 85-89.
https://hdl.handle.net/21.15107/rcub_farfar_212
Stanojević N, Jelić-Ivanović Z, Durović S, Spasojević-Kalimanovska V. The role of transforming growth factor-beta in identifying patients with coronary artery disease. in Jugoslovenska medicinska biohemija. 1999;18(2-3):85-89.
https://hdl.handle.net/21.15107/rcub_farfar_212 .
Stanojević, N, Jelić-Ivanović, Zorana, Durović, S, Spasojević-Kalimanovska, Vesna, "The role of transforming growth factor-beta in identifying patients with coronary artery disease" in Jugoslovenska medicinska biohemija, 18, no. 2-3 (1999):85-89,
https://hdl.handle.net/21.15107/rcub_farfar_212 .